JP2016501020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501020A5 JP2016501020A5 JP2015544499A JP2015544499A JP2016501020A5 JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- seq
- virus
- influenza
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 49
- 241000712431 Influenza A virus Species 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 26
- 206010022000 influenza Diseases 0.000 claims description 24
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 17
- 208000037797 influenza A Diseases 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- 108091034135 Vault RNA Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000000991 chicken egg Anatomy 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 229940126581 whole-virion vaccine Drugs 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732809P | 2012-12-03 | 2012-12-03 | |
| US61/732,809 | 2012-12-03 | ||
| PCT/EP2013/075294 WO2014086732A2 (en) | 2012-12-03 | 2013-12-02 | Influenza virus reassortment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501020A JP2016501020A (ja) | 2016-01-18 |
| JP2016501020A5 true JP2016501020A5 (enExample) | 2017-01-19 |
| JP6421128B2 JP6421128B2 (ja) | 2018-11-07 |
Family
ID=49713076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544499A Active JP6421128B2 (ja) | 2012-12-03 | 2013-12-02 | リアソータントインフルエンザａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9708585B2 (enExample) |
| EP (1) | EP2925356A2 (enExample) |
| JP (1) | JP6421128B2 (enExample) |
| KR (1) | KR20150110494A (enExample) |
| CN (1) | CN105120893B (enExample) |
| AU (2) | AU2013354219A1 (enExample) |
| BR (1) | BR112015012380A2 (enExample) |
| CA (1) | CA2893429A1 (enExample) |
| HK (1) | HK1214959A1 (enExample) |
| MX (1) | MX2015006927A (enExample) |
| WO (1) | WO2014086732A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6421128B2 (ja) * | 2012-12-03 | 2018-11-07 | ノバルティス アーゲー | リアソータントインフルエンザａウイルス |
| US10323231B2 (en) * | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
| EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| GB201602535D0 (en) * | 2016-02-12 | 2016-03-30 | Univ Edinburgh | Improved flu vaccine yield |
| KR20200040750A (ko) * | 2017-08-28 | 2020-04-20 | 잇판사이단호진한다이비세이부쯔뵤우겐큐우카이 | 리소턴트 인플루엔자 바이러스의 단계적 작출 방법 |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| JP7320601B2 (ja) * | 2018-09-11 | 2023-08-03 | 上▲海▼市公共▲衛▼生▲臨▼床中心 | 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用 |
| KR101954904B1 (ko) | 2018-10-15 | 2019-03-06 | 남종규 | 복층의 태양광 설치 구조 |
| CN111647610B (zh) * | 2020-06-02 | 2021-09-03 | 扬州大学 | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| PT1098961E (pt) | 1998-06-12 | 2008-04-23 | Mount Sinai School Of Med Of T | Vírus atenuados produzidos por engenharia genética indutores de interferão |
| HUP0202846A3 (en) | 1999-09-24 | 2003-12-29 | Smithkline Beecham Biolog | Intranasal influenza virus vaccine |
| JP4698112B2 (ja) | 2000-03-03 | 2011-06-08 | 一般財団法人化学及血清療法研究所 | 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法 |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| EP1361889A1 (en) | 2001-02-23 | 2003-11-19 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
| DK1361890T3 (da) | 2001-02-23 | 2011-06-27 | Glaxosmithkline Biolog Sa | Influenzavaccineformuleringer til intradermal indgift |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| PT1742659E (pt) | 2004-04-05 | 2013-06-03 | Pah Usa 15 Llc | Emulsões de óleo em água microfluidizadas e composições de vacinas |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| AU2005245943A1 (en) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Process for the production of an influenza vaccine |
| ES2526170T3 (es) | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| EP1917352A4 (en) | 2005-06-21 | 2009-03-25 | Medimmune Vaccines Inc | METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| EA014062B1 (ru) | 2005-11-01 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг | Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007126810A2 (en) * | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| CA2646526C (en) | 2006-04-19 | 2016-01-12 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral rna in canine cells |
| HRP20130023T1 (hr) | 2006-10-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans |
| EA200900784A1 (ru) | 2006-12-06 | 2009-12-30 | Новартис Аг | Вакцины, включающие антиген из четырех штаммов вируса гриппа |
| WO2008157419A2 (en) * | 2007-06-13 | 2008-12-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| JP5686741B2 (ja) * | 2008-12-16 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | インフルエンザワクチンの生成 |
| EP2233152A1 (en) * | 2009-03-24 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade Ag | High growth reassortant influenza A virus |
| EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
| NZ617191A (en) * | 2009-06-25 | 2015-06-26 | Medimmune Llc | Swine influenza hemagglutinin variants |
| US9821052B2 (en) | 2009-07-31 | 2017-11-21 | Seqirus UK Limited | Reverse genetics systems |
| CN103025350A (zh) * | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| JP6421128B2 (ja) * | 2012-12-03 | 2018-11-07 | ノバルティス アーゲー | リアソータントインフルエンザａウイルス |
-
2013
- 2013-12-02 JP JP2015544499A patent/JP6421128B2/ja active Active
- 2013-12-02 BR BR112015012380A patent/BR112015012380A2/pt not_active IP Right Cessation
- 2013-12-02 WO PCT/EP2013/075294 patent/WO2014086732A2/en not_active Ceased
- 2013-12-02 US US14/648,886 patent/US9708585B2/en active Active
- 2013-12-02 CN CN201380071503.1A patent/CN105120893B/zh active Active
- 2013-12-02 AU AU2013354219A patent/AU2013354219A1/en not_active Abandoned
- 2013-12-02 EP EP13799527.0A patent/EP2925356A2/en not_active Withdrawn
- 2013-12-02 KR KR1020157016758A patent/KR20150110494A/ko not_active Ceased
- 2013-12-02 HK HK16102968.6A patent/HK1214959A1/zh unknown
- 2013-12-02 CA CA2893429A patent/CA2893429A1/en not_active Abandoned
- 2013-12-02 MX MX2015006927A patent/MX2015006927A/es unknown
-
2017
- 2017-06-13 US US15/621,270 patent/US10500266B2/en active Active
-
2018
- 2018-09-19 AU AU2018232956A patent/AU2018232956B2/en active Active
-
2019
- 2019-10-28 US US16/665,104 patent/US20200155666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501020A5 (enExample) | ||
| JP2016509864A5 (enExample) | ||
| JP2015119730A5 (enExample) | ||
| Milián et al. | Current and emerging cell culture manufacturing technologies for influenza vaccines | |
| Thomas et al. | Cell-mediated protection in influenza infection | |
| Cauldwell et al. | Viral determinants of influenza A virus host range | |
| Ping et al. | Development of high-yield influenza A virus vaccine viruses | |
| Zhou et al. | Characterization of uncultivable bat influenza virus using a replicative synthetic virus | |
| Horimoto et al. | Enhanced growth of seed viruses for H5N1 influenza vaccines | |
| Chen et al. | The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response | |
| Feng et al. | Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence | |
| Petiot et al. | Influenza viruses production: evaluation of a novel avian cell line DuckCelt®-T17 | |
| JP2012511914A5 (enExample) | ||
| Jang et al. | Principles underlying rational design of live attenuated influenza vaccines | |
| JP2013179943A5 (enExample) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| Neumann et al. | Identification of amino acid changes that may have been critical for the genesis of A (H7N9) influenza viruses | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Van Wielink et al. | Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines | |
| Abdoli et al. | Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| Mostafa et al. | Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments | |
| Silva et al. | Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing | |
| Koudstaal et al. | Suitability of PER. C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics | |
| CA2880409A1 (en) | Production of infectious influenza viruses |